F. Cognetti

6.8k total citations · 1 hit paper
129 papers, 4.8k citations indexed

About

F. Cognetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, F. Cognetti has authored 129 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in F. Cognetti's work include Cancer Treatment and Pharmacology (42 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Treatments and Mutations (19 papers). F. Cognetti is often cited by papers focused on Cancer Treatment and Pharmacology (42 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Treatments and Mutations (19 papers). F. Cognetti collaborates with scholars based in Italy, United States and India. F. Cognetti's co-authors include M. Bolla, C. Domenge, M. van Glabbeke, Frédéric Rolland, Jacques Bernier, Jean-Louis Lefèbvre, Jean Bourhis, Richard Greiner, Anne Kirkpatrick and Mahmut Özsahin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

F. Cognetti

125 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer

2004 2.2k citations Jacques Bernier, C. Domenge et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by F. Cognetti

Since Specialization

Citations

This map shows the geographic impact of F. Cognetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Cognetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Cognetti more than expected).

Fields of papers citing papers by F. Cognetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Cognetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Cognetti. The network helps show where F. Cognetti may publish in the future.

Co-authorship network of co-authors of F. Cognetti

This figure shows the co-authorship network connecting the top 25 collaborators of F. Cognetti. A scholar is included among the top collaborators of F. Cognetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Cognetti. F. Cognetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nanoparticle Albumin-Bound Paclitaxel/Liposomal-Encapsulated Doxorubicin in HER2-Negative Metastatic Breast Cancer Patients 2020 ·Future Oncology ·Alessandra Fabi, G. Ferretti, Paola Malaguti, (unknown), Cecilia Nisticò, Grazia Arpino, Paola Papaldo, Michelangelo Russillo, (unknown), Francesco Schettini, Diana Giannarelli, F. Cognetti	10
2	Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study 2017 ·Annals of Oncology ·(unknown), Claudia Bighin, Fabio Puglisi, Lorenzo Gerratana, M. De Laurentis, Andrea Fontana, (unknown), (unknown), Filippo Montemurro, Grazia Arpino, Francesca Poggio, (unknown), Chiara Dellepiane, Eva Blondeaux, (unknown), F. Cognetti, Ornella Garrone, Anna Turletti, (unknown), Lucia Del Mastro	1
3	Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants? 2006 ·CHEST Journal ·G. Ferretti, Emilio Bria, Diana Giannarelli, Paolo Carlini, Alessandra Felici, Mario Mandalà, Paola Papaldo, Alessandra Fabi, Mariangela Ciccarese, Federica Cuppone, (unknown), Carmen Nuzzo, E. Terzoli, F. Cognetti	26
4	Adjuvant chemotherapy in muscle‐invasive bladder carcinoma 2006 ·Cancer ·Enzo Maria Ruggeri, Diana Giannarelli, Emilio Bria, Paolo Carlini, Alessandra Felici, Fabrizio Nelli, Michele Gallucci, F. Cognetti, (unknown)	53
5	Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL 2005 ·Annals of Oncology ·Francesco Di Costanzo, Silvia Gasperoni, Paola Papaldo, Domenico Bilancia, Luigi Manzione, Elisa Landucci, Francesca Mazzoni, F. Cognetti	11
6	Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study 2005 ·Oncology ·Cecilia Nisticò, F. Cognetti, Luciano Frontini, Sandro Barni, G. Ferretti, Emilio Bria, Michèle Milella, Carlo Garufi, Federica Cuppone, (unknown), Paolo Carlini, E. Terzoli	9
7	Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer breakdown → 2004 ·New England Journal of Medicine ·Jacques Bernier, C. Domenge, Mahmut Özsahin, Katarzyna Łukawska‐Matuszewska, Jean-Louis Lefèbvre, Richard Greiner, J. Giralt, P. Maingon, Frédéric Rolland, M. Bolla, F. Cognetti, Jean Bourhis, Anne Kirkpatrick, M. van Glabbeke	2209
8	Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer 2003 ·Annals of Oncology ·Massimo Zeuli, (unknown), Maria Simona Pino, Teresa Gamucci, Antonio Gabriele, Virginia Ferraresi, Diana Giannarelli, F. Cognetti	46
9	Accelerated Hyperfractionated Radiotherapy and Concurrent Protracted Venous Infusion Chemotherapy in Locally Advanced Head and Neck Cancer 2002 ·American Journal of Clinical Oncology ·Giorgio Arcangeli, Biancamaria Saracino, Donatella Tirindelli Danesi, Enrico de Campora, Giuseppe Giovinazzo, F. Cognetti, Paolo Carlini, Stefano Arcangeli, Antonio Mecozzi	4
10	A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule 2001 ·Cancer Chemotherapy and Pharmacology ·L. Serrone, Massimo Zeuli, Teresa Gamucci, Marco Nardi, F. Cognetti	11
11	Toxicity and Activity of Docetaxel in Anthracycline-Pretreated Breast Cancer Patients 2000 ·American Journal of Clinical Oncology ·Virginia Ferraresi, Michèle Milella, Angela Vaccaro, (unknown), Paola Papaldo, Cecilia Nisticò, (unknown), Annelisa Marsella, (unknown), Diana Giannarelli, E. Terzoli, F. Cognetti	30
12	Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study 1999 ·British Journal of Cancer ·Angelo Fedele Scinto, Virginia Ferraresi, Michèle Milella, Enrico Tucci, (unknown), (unknown), Michele Del Vecchio, (unknown), Marco Nardi, F. Cognetti	10
13	Paclitaxel as Salvage Therapy in Advanced Pretreated Ovarian Cancer: A Phase II Study 1997 ·American Journal of Clinical Oncology ·Marco Nardi, (unknown), Salvatore De Marco, F. Cognetti, Annunziata Iacovelli, (unknown), F. Calabresi	11
14	Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck 1996 ·Annals of Oncology ·Jaap Verweij, P.H.M. de Mulder, Alexander de Graeff, J. B. Vermorken, (unknown), (unknown), Jan H. Schornagel, F. Cognetti, A. Kirkpatrick, Tarek Sahmoud, J.-L. Lefebvre	47
15	Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. 1995 ·Journal of Clinical Oncology ·Jan H. Schornagel, Jaap Verweij, (unknown), F. Cognetti, Jan B. Vermorken, P Cappelaere, P. Armand, J. Wildiers, Alexander de Graeff, M. Clavel	64
16	A phase II trial of vinorelbine and thiotepa in metastatic breast cancer 1995 ·Annals of Oncology ·Alessandra Fabi, (unknown), Antonella Savarese, (unknown), Federica Tomao, (unknown), F. Cognetti	11
17	A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck 1994 ·Annals of Oncology ·Paola Pinnarò, Maria Cecilia Cercato, Diana Giannarelli, Paolo Carlini, Michele Del Vecchio, (unknown), F Marzetti, Michèle Milella, F. Cognetti	16
18	Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Head and Neck Cancer Cooperative Group 1993 ·Annals of Oncology ·J. B. Vermorken, Jaco J. Verweij, (unknown), F. Cognetti, M. Clavel, Sjoerd Rodenhuis, A. Kirkpatrick, (unknown)	69
19	Toxic dermatitis induced by 10-ethyl-10-deazaaminopterin (10-EdAM), a novel antifolate 1990 ·Cancer ·Jaap Verweij, Jan H. Schornagel, Pieter De Mulder, Sonja C. Henzen‐Logmans, F. Cognetti, (unknown), Jan B. Vermorken	10
20	Combination chemotherapy (CABO) prior to radiation for locally advanced inoperable squamous cell carcinoma of the head and neck 1984 ·Journal of Experimental & Clinical Cancer Research ·F. Cognetti, Paola Pinnarò, Paolo Carlini	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact